Dry Eye: Developing Drugs for Treatment

On 16 December 2020 the FDA announced the availability of the draft guidance for industry. Comments may be submitted until 17 March 2021.

This guidance is intended to provide recommendations to sponsors regarding eligibility criteria, trial design considerations, and efficacy endpoints to enhance clinical trial data quality and to foster greater efficiency in development programs for drugs for the treatment of dry eye.

Read more online 
Copyright Widler & Schiemann AG 2020. All Rights Reserved. /